Lipopolysaccharide regulates MMP-9 expression through TLR4/NF-κB signaling in human arterial smooth muscle cells

Molecular Medicine Reports

Volumn 6, Issue 4, 2012, Pages 774-778

  Li, Hongli ^a   Xu, Hao ^a   Sun, Baogui ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Lipopolysaccharide; Matrix metalloproteinases; Nuclear factor B; Toll like receptor 4

Indexed keywords

GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; PYRROLIDINE DITHIOCARBAMATE; TOLL LIKE RECEPTOR 4;

ARTERY MUSCLE; ARTICLE; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN ARTERIAL SMOOTH MUSCLE CELL; HUMAN CELL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOOTH MUSCLE FIBER; UPREGULATION;

ANTIOXIDANTS; CELLS, CULTURED; HUMANS; LIPOPOLYSACCHARIDES; MATRIX METALLOPROTEINASE 9; MYOCYTES, SMOOTH MUSCLE; NF-KAPPA B; PROTEIN BINDING; PYRROLIDINES; RNA, MESSENGER; SIGNAL TRANSDUCTION; THIOCARBAMATES; TOLL-LIKE RECEPTOR 4;

EID: 84865176924     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.1010     Document Type: Article

References (22)

1. Nagase H: Activation mechanisms of matrix metalloproteinases. Biol Chem 378: 151-160, 1997.
2. Creemers EE, Cleutjens JP, Smits JF and Daemen MJ: Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ Res 89: 201-210, 2001. (Pubitemid 34132679)
3. Lancelot E, Amirbekian V, Brigger I, Raynaud JS, Ballet S, David C, Rousseaux O, Le Greneur S, Port M, Lijnen HR, Bruneval P, Michel JB, Ouimet T, Roques B, Amirbekian S, Hyafil F, Vucic E, Aguinaldo JG, Corot C and Fayad ZA: Evaluation of matrix metalloproteinases in atherosclerosis using a novel noninvasive imaging approach. Arterioscler Thromb Vasc Biol 28: 425-432, 2008.
4. Furman C, Luo Z, Walsh K, Duverger N, Copin C, Fruchart JC and Rouis M: Systemic tissue inhibitor of metalloproteinase-1 gene delivery reduces neointimal hyperplasia in balloon-injured rat carotid artery. FEBS Lett 531: 122-126, 2002. (Pubitemid 35341181)
5. Fedak PW, Moravec CS, McCarthy PM, Altamentova SM, Wong AP, Skrtic M, Verma S, Weisel RD and Li RK: Altered expression of disintegrin metalloproteinases and their inhibitor in human dilated cardiomyopathy. Circulation 113: 238-245, 2006.
6. Tziakas DN, Chalikias GK, Papaioakeim M, Hatzinikolaou EI, Stakos DA, Tentes IK, Papanas N, Kortsaris A, Maltezos E and Hatseras DI: Comparison of levels of matrix metalloproteinase-2 and -3 in patients with ischemic cardiomyopathy versus nonischemic cardiomyopathy. Am J Cardiol 96: 1449-1451, 2005. (Pubitemid 41566631)
7. Sun Y, Zhang JQ, Zhang J and Lamparter S: Cardiac remodeling by fibrous tissue after infarction in rats. J Lab Clin Med 135: 316-323, 2000. (Pubitemid 30213547)
8. Ogawa M, Suzuki J, Hishikari K, Takayama K, Tanaka H and Isobe M: Clarithromycin attenuates acute and chronic rejection via matrix metalloproteinase suppression in murine cardiac transplantation. J Am Coll Cardiol 51: 1977-1985, 2008. (Pubitemid 351636452)
9. Lee SO, Chang YC, Whang K, Kim CH and Lee IS: Role of NAD(P)H:quinone oxidoreductase 1 on tumor necrosis factor-alpha-induced migration of human vascular smooth muscle cells. Cardiovasc Res 76: 331-339, 2007. (Pubitemid 350198593)
10. Otero-Viñas M, Llorente-Cortés V, Peña E, Padró T and Badimon L: Aggregated low density lipoproteins decrease metalloproteinase-9 expression and activity in human coronary smooth muscle cells. Atherosclerosis 194: 326-333, 2007. (Pubitemid 47513094)
11. Cho A and Reidy MA: Matrix metalloproteinase-9 is necessary for the regulation of smooth muscle cell replication and migration after arterial injury. Circ Res 91: 845-851, 2002. (Pubitemid 35285083)
12. Abe K, Ikeda T, Wake K, Sato T, Sato T and Inoue H: Glycyrrhizin prevents lipopolysaccharide/D-galactosamine-induced liver injury through down-regulation of matrix metalloproteinase-9 in mice. J Pharm Pharmacol 60: 91-97, 2008.
13. Pagenstecher A, Stalder AK and Kincaid CL: Regulation of matrix metalloproteinases and their inhibitor genes in lipopolysaccharide- induced endotoxemia in mice. Am J Pathol 157: 197-210, 2000. (Pubitemid 30641737)
14. Lin SJ, Lee IT, Chen YH, Lin FY, Sheu LM, Ku HH, Shiao MS, Chen JW and Chen YL: Salvianolic acid B attenuates MMP-2 and MMP-9 expression in vivo in apolipoprotein-E-deficient mouse aorta and in vitro in LPS-treated human aortic smooth muscle cells. J Cell Biochem 100: 372-384, 2007.
15. Beswick RA, Zhang H, Marable D, Catravas JD, Hill WD and Webb RC: Long-term antioxidant administration attenuates mineralocorticoid hypertension and renal inflammatory response. Hypertension 37: 781-786, 2001. (Pubitemid 32199066)
16. Hongli Li and Baogui Sun: Toll-like receptor 4 in atherosclerosis. J Cell Mol Med 11: 88-95, 2007.
17. Watari M, Watari H, Nachamkin I and Strauss JF: Lipopolysaccharide induces expression of genes encoding pro-inflammatory cytokines and the elastin-degrading enzyme, cathepsin S, in human cervical smooth-muscle cells. J Soc Gynecol Invest 7: 190-198, 2000. (Pubitemid 30349165)
18. Fiotti N, Altamura N, Fisicaro M, Carraro N, Adovasio R, Sarra VM, Uxa L, Guarnieri G, Baxter BT and Giansante C: MMP-9 microsatellite polymorphism: association with the progression of intima-media thickening and constrictive remodeling of carotid atherosclerotic plaques. Atherosclerosis 182: 287-292, 2005. (Pubitemid 41267196)
19. Tsai CS, Lin FY, Chen YH, Yang TL, Wang HJ, Huang GS, Lin CY, Tsai YT, Lin SJ and Li CY: Cilostazol attenuates MCP-1 and MMP-9 expression in vivo in LPS-administrated balloon-injured rabbit aorta and in vitro in LPS-treated monocytic THP-1 cells. J Cell Biochem 103: 54-66, 2008.
20. Bea F, Kreuzer J, Preusch M, Schaab S, Isermann B, Rosenfeld ME, Katus H and Blessing E: Melagatran reduces advanced atherosclerotic lesion size and may promote plaque stability in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 26: 2787-2792, 2006.
21. Lee SY, Kim HJ, Lee WJ, Joo SH, Jeon SJ, Kim JW, Kim HS, Han SH, Lee J, Park SH, Cheong JH, Kim WK, Ko KH and Shin CY: Differential regulation of matrix metalloproteinase-9 and tissue plasminogen activator activity by the cyclic-AMP system in lipopolysaccharide-stimulated rat primary astrocytes. Neurochem Res 33: 2324-2334, 2008.
22. Marcet-Palacios M, Ulanova M, Duta F, Puttagunta L, Munoz S, Gibbings D, Radomski M, Cameron L, Mayers I and Befus AD: The transcription factor Wilms tumor 1 regulates matrix metalloproteinase-9 through a nitric oxide-mediated pathway. J Immunol 179: 256-265, 2007. (Pubitemid 46986541)